Breaking News Instant updates and real-time market news.

ARQL

ArQule

$9.26

0.01 (0.11%)

, GTHX

G1 Therapeutics

$29.78

-0.02 (-0.07%)

08:22
08/12/19
08/12
08:22
08/12/19
08:22

BTIG to hold a conference

Biotechnology Conference 2019 will be held in New York on August 12.

ARQL

ArQule

$9.26

0.01 (0.11%)

GTHX

G1 Therapeutics

$29.78

-0.02 (-0.07%)

XAIR

Beyond Air

$5.00

0.02 (0.40%)

XFOR

X4 Pharmaceuticals

$12.25

-0.01 (-0.08%)

XNCR

Xencor

$37.47

0.56 (1.52%)

VRNA

Verona Pharma

$4.50

-0.1 (-2.17%)

VYGR

Voyager Therapeutics

$20.55

-0.12 (-0.58%)

EIGR

Eiger BioPharmaceuticals

$10.20

0.18 (1.80%)

TCRR

TCR2 Therapeutics

$15.28

-0.59 (-3.72%)

TCON

TRACON Pharmaceuticals

$0.45

0.02 (4.65%)

ESPR

Esperion

$37.70

-1.27 (-3.26%)

RCUS

Arcus Biosciences

$7.30

-0.155 (-2.08%)

SGMO

Sangamo

$11.75

-0.22 (-1.84%)

CRSP

Crispr Therapeutics

$50.20

1.22 (2.49%)

FIXX

Homology Medicines

$15.79

(0.00%)

SNDX

Syndax

$9.94

-0.08 (-0.80%)

  • 12

    Aug

  • 13

    Aug

  • 04

    Sep

  • 09

    Sep

  • 12

    Sep

ARQL ArQule
$9.26

0.01 (0.11%)

06/14/19
ROTH
06/14/19
NO CHANGE
Target $13
ROTH
Buy
ArQule price target raised to $13 from $10 at Roth Capital
Roth Capital analyst Tony Butler said he is optimistic about the efficacy and safety profile of ARQ 531 following the company's presentation of trial data, investor call and his talk with management. However, he thinks the key uncertainty now is durability of responses, which he highlights as important given the refractory population and the fact that ibrutinib was also based on survival data. He has raised his view of the probability of success for ARQ 531 to 50% from 33% previously and increased his price target to $13 on ArQule shares, on which he keeps Buy rating.
06/17/19
ROTH
06/17/19
NO CHANGE
Target $20
ROTH
Buy
ArQule price target raised to $20 from $10 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for ArQule to $20 from $10 after the company presented updated data from its first-in-human, single-arm Phase 1 study of ARQ 531, the first oral reversible BTK inhibitor for both wild-type and ibrutinib-resistant BTK-c481S mutation. The analyst reiterates a Buy rating on the shares.
05/29/19
RILY
05/29/19
NO CHANGE
Target $11
RILY
Buy
ArQule price target raised to $11 from $6.75 at B. Riley FBR
B. Riley FBR analyst George Zavoico raised his price target for ArQule to $11 from $6.75 ahead of what he expects will be "positive" Phase I safety and efficacy results for ARQ531 at the European Hematology Association conference in June. The analyst reiterates a Buy rating on the shares.
06/19/19
RBCM
06/19/19
NO CHANGE
Target $12
RBCM
Outperform
ArQule price target raised to $12 from $10 at RBC Capital
RBC Capital analyst Gregory Ranza raised his price target on ArQule to $12 and kept his Outperform rating, citing the company's "impressive data" and "high enthusiasm" for its BTKi program ARQ 531 in B-cell malignancies demonstrated at the European Hematology Association Congress this week. The analyst adds that his new price target reflects the improving prospects for ARQ 531 success, along with his "increasing confidence" that an effective path awaits ArQule toward a "meaningful" Chronic Lymphocytic Leukemia market opportunity.
GTHX G1 Therapeutics
$29.78

-0.02 (-0.07%)

02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
B. Riley FBR starts G1 Therapeutics with Buy rating, $55 price target
B. Riley FBR analyst Harshita Polishetty initiated coverage of G1 Therapeutics with a Buy rating and $55 price target. G1's lead candidate, trilaciclib, has the potential to address myelotoxicity and improve overall survival in chemotherapy-associated treatment regimens, Polishetty tells investors in a research note. Further, Lerociclib, although fourth to market, demonstrates potential to be best in class given its clean safety profile thus far adds the analyst. She also believes G1T48 allows for competitive pricing when both lerociclib and G1T48 hit the market.
02/07/19
RILY
02/07/19
INITIATION
Target $55
RILY
Buy
G1 Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Harshita Polishetty started G1 Therapeutics with a Buy rating and $55 price target.
08/08/19
JPMS
08/08/19
UPGRADE
Target $45
JPMS
Overweight
G1 Therapeutics upgraded to Overweight from Neutral at JPMorgan
JPMorgan analyst Anupam Rama upgraded G1 Therapeutics to Overweight from Neutral and raised his price target for the shares to $45 from $38. The analyst sees a "string of important key catalysts" in the second half of 2019 and first half of 2020 for G1's pipeline. Rama now includes G1T48 in his model with initial phase 1 data in ER+/HER2- breast cancer coming at the end of September. Further, at current share levels, the analyst believes limited value is being ascribed to lerociclib.
06/18/19
HCWC
06/18/19
NO CHANGE
HCWC
G1 Therapeutics trial results 'important,' says H.C. Wainwright
H.C. Wainwright analyst Edward White maintained a Buy rating and $71 price target on G1 Therapeutics. The analyst noted that G1 Therapeutics' topline OS improvements from its randomized, open-label Phase 2 trial evaluating trilaciclib in metastatic triple-negative breast cancer were "statistically significant in both treatment arms compared with the control arm." White believes that "an OS benefit seen in a small three-arm trial like this is an important result" and added that "the company can now pursue an efficacy benefit as well as the myelopreservation pathway... for commercialization."
XAIR Beyond Air
$5.00

0.02 (0.40%)

XFOR X4 Pharmaceuticals
$12.25

-0.01 (-0.08%)

06/07/19
STFL
06/07/19
INITIATION
Target $27
STFL
Buy
X4 Pharmaceuticals initiated with a Buy at Stifel
Stifel analyst Stephen Willey started X4 Pharmaceuticals with a Buy rating and $27 price target. The biological validation associated with CXCR4 inhibition in rare diseases of immunodeficiency and certain types of cancer, along with a "clear pathway" to commercialization with a "best-in- class asset" in WHIM syndrome create an attractive investment thesis for X4, Willey tells investors in a research note. He believes the Phase 3 development plans for mavorixafor in WHIM syndrome are "significantly de-risked."
06/05/19
COWN
06/05/19
INITIATION
COWN
Outperform
X4 Pharmaceuticals initiated with an Outperform at Cowen
Cowen analyst Marc Frahm started X4 Pharmaceuticals with an Outperform rating.
05/21/19
ADAM
05/21/19
INITIATION
Target $27
ADAM
Buy
X4 Pharmaceuticals initiated with a Buy at Canaccord
Canaccord analyst Arlinda Lee initiated X4 Pharmaceuticals with a Buy rating and $27 price target. In a research note to investors, Lee says she views clinical data for mavorixafor, the company's oral, daily CXCR4 agonist, showing release of white blood cells from the bone marrow into periphery as indicative of on-target effect of CXCR4 signaling inhibition and would expect affirmation from the planned pivotal study of mavorixafor in rare, immune disease WHIM. Lee also expects X4 to pursue other rare diseases wherein release of white blood cells could be clinically meaningful.
XNCR Xencor
$37.47

0.56 (1.52%)

08/08/19
CANT
08/08/19
NO CHANGE
Target $40
CANT
Overweight
Xencor post earnings selloff yesterday overdone, says Cantor Fitzgerald
Cantor Fitzgerald analyst Alethia Young views the post-earnings selloff yesterday in shares of Xencor as overdone. While the company shifted timelines for SSTR2xCD3 and PD-1xCTLA-4 assets from end of 2019 to the first half of 2020, the selloff yesterday was likely an overreaction, Young tells investors in a research note. She thinks Xencor's platform value remains the same and views the company as very well capitalized with $625M in cash. The analyst reiterates an Overweight rating on the shares with a $40 price target.
08/08/19
ADAM
08/08/19
NO CHANGE
Target $52
ADAM
Buy
Xencor price target raised to $52 from $45 at Canaccord
Canaccord analyst Arlinda Lee raised her price target on Xencor to $52 from $45 citing its commercial product Xtend which is already generating sales, multiple partnered programs, and wholly owned programs progressing through the clinic. Lee reiterated her Buy rating on Xencor shares.
08/07/19
WEDB
08/07/19
NO CHANGE
Target $54
WEDB
Outperform
Xencor price target raised to $54 from $43 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Xencor (XNCR) to $54 from $43 as he believes it remains a de-risked platform name, no near-term cash needs, and with support for its valuation from Alexion (ALXN) Ultomiris royalties, and a potentially more significant royalty stream from tafasitamab with multiple early-stage pipeline candidates to provide future upside. The analyst reiterates an Outperform rating on Xencor's shares.
08/07/19
GUGG
08/07/19
DOWNGRADE
GUGG
Neutral
Xencor downgraded to Neutral from Buy at Guggenheim
Guggenheim analyst Michael Schmidt downgraded Xencor to Neutral from Buy saying he's looking for a more attractive entry point.
VRNA Verona Pharma
$4.50

-0.1 (-2.17%)

04/17/19
BTIG
04/17/19
INITIATION
BTIG
Buy
Verona Pharma initiated with a Buy at BTIG
01/14/19
WEDB
01/14/19
NO CHANGE
Target $56
WEDB
Outperform
Wedbush says time to buy Verona Pharma, reaction to 3 day combo Phase 2 overdone
Wedbush analyst analyst is Liana Mousssatos notes that Verona Pharma is developing Ensifentrine as a treatment candidate for respiratory diseases such as COPD, CF and potentially asthma, and multiple exploratory Phase 2 trials for COPD have been conducted with the latest testing this new mechanism on top of dual LAMA/LABA and triple background therapy. The analyst adds that topline results were reported and speculates the negative overreaction in stock value is due to the lack of statistical significance for the primary endpoint. While Moussatos acknowledges that lack of statistical significance is "annoying," she believes it is not a deal-breaker for approval. The analyst sees that while the high dose contributed to the lack of statistical significance for the primary endpoint, the low dose has a consistently positive effect in the various analyses and may be a dose used in a future Phase 3 trial. Moussatos considers the weakness to be a buying opportunity, and reiterates an Outperform rating and $56 price target on the shares.
04/17/19
BTIG
04/17/19
INITIATION
Target $17
BTIG
Buy
Verona Pharma initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Verona Pharma with a Buy rating and a price target of $17, citing the company's development of RPL554 for Chronic Obstructive Pulmonary Disease, which he sees as an "enormous and underserved market of about 16M patients in the U.S." The analyst states that while the market for COPD treatment is "crowded with bronchodilators", he sees Verona Phama's "highly active and patient-friendly anti-inflammatory drug like RPL554" as an important advance and looks ahead to its pivotal trial study that may begin later this year.
VYGR Voyager Therapeutics
$20.55

-0.12 (-0.58%)

05/08/19
HCWC
05/08/19
NO CHANGE
Target $26
HCWC
Buy
Voyager Therapeutics price target raised to $26 from $22 at H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay raised his price target for Voyager Therapeutics to $26 from $22 saying execution was the consistent theme during the company's Q1 results. The analyst sees a "solid" balance sheet and "compelling" partnerships. He keeps a Buy rating on the shares.
06/18/19
WEDB
06/18/19
NO CHANGE
Target $36
WEDB
Outperform
Voyager Therapeutics price target raised to $36 from $27 at Wedbush
Wedbush analyst David Nierengarten raised his price target for Voyager Therapeutics to $36 from $27 as we begin to incorporate Huntington's disease gene therapy candidate VY-HTT01 into his valuation, assigning it a preliminary program valuation of about $9.5/share. The analyst reiterates an Outperform rating on the shares.
06/20/19
NOMU
06/20/19
NO CHANGE
Target $37
NOMU
Buy
Voyager Therapeutics price target raised to $37 from $26 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Voyager Therapeutics (VYGR) to $37 from $26 after the company announced a restructured deal with Sanofi (SNY). Voyager now has worldwide rights to VY-HTT01 for Huntington's disease, and the ex-U.S. rights to VYFXN01 for Friedreich's ataxia have now been transferred to Neurocrine (NBIX), Marai tells investors in a research note. He believes obtaining the full rights to HTT01 is a positive for Voyager, especially after Roche (RHHBY) "posted positive derisking data." Marai reiterates a Buy rating on Voyager Therapeutics.
07/12/19
MSCO
07/12/19
NO CHANGE
Target $28
MSCO
Equal Weight
Voyager Therapeutics price target raised to $28 from $21 at Morgan Stanley
Morgan Stanley analyst Jeffrey Hung raised his price target on Voyager Therapeutics (VYGR) shares to $28 from $21 after the company recently announced that it will be getting back rights to VY-HTT01 for Huntington's disease in a restructuring of its partnership with Sanofi Genzyme (SNY). While early in development, Hungs think VY-HTT01 could be a roughly $900M product for Voyager. Although he appreciates the opportunity in Huntington's and is "constructive" on VY-AADC in Parkinson's, Hung keeps an Equal Weight rating on Voyager shares, citing what he sees as limited near-term clinical catalysts.
EIGR Eiger BioPharmaceuticals
$10.20

0.18 (1.80%)

06/26/19
SBSH
06/26/19
INITIATION
Target $22
SBSH
Buy
Eiger BioPharmaceuticals initiated with a Buy at Citi
Citi analyst Yigal Nochomovitz initiated Eiger BioPharmaceuticals with a Buy rating and $22 price target, noting that he assumes 60% odds of success for lonafarnib and 50% odds of success for pegylated interferon, both of which the company is developing to treat hepatitis D. Eiger is also developing lonafarnib for progeria, a fatal rare disease marked by premature aging, noted Nochomovitz, who assumes a 90% chance of success in that indication.
01/29/19
01/29/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Dell Technologies (DELL) initiated with an Outperform at Raymond James. 2. MasterCard (MA) and Visa (V) were initiated with a Buy at Jefferies. 3. Eiger BioPharmaceuticals (EIGR) initiated with an Outperform at Baird. 4. Arena Pharmaceuticals (ARNA) assumed with an Overweight at Cantor Fitzgerald. 5. Southern Copper (SCCO) reinstated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
06/18/19
JEFF
06/18/19
NO CHANGE
Target $27
JEFF
Buy
Eiger breakthrough designation a surprise, says Jefferies
Jefferies analyst Maury Raycroft says the Breakthrough Therapy Designation for Eiger BioPharmaceuticals' avexatide in post-bariatric hypoglycemia came as a surprise. The company's PBH program is more under-the-radar for investors, given its focus on hepatitis delta virus and the near-term new drug application filing for Progeria syndrome and Progeroid Laminopathies, Raycroft tells investors in a res research note. He views last night's news as a positive and keeps a Buy rating on Eiger BioPharmaceuticals with a $27 price target.
04/24/19
WEDB
04/24/19
NO CHANGE
Target $35
WEDB
Outperform
Eiger BioPharmaceuticals price target lowered to $35 from $43 at Wedbush
Wedbush analyst Liana Moussatos lowered her price target for Eiger BioPharmaceuticals to $35 from $43 due to financing share dilution. The analyst notes that Eiger recently announced pricing of a follow-on offering to raise approximately $49.50M. Moussatos estimates net proceeds of $44.55M and project cash runway into Q1 of 2021, which covers important clinical, regulatory and commercial activities. She reiterates an Outperform rating on the shares.
TCRR TCR2 Therapeutics
$15.28

-0.59 (-3.72%)

05/31/19
ROTH
05/31/19
INITIATION
Target $16
ROTH
Neutral
TCR2 Therapeutics initiated with a Neutral at Roth Capital
Roth Capital analyst Tony Butler started TCR2 Therapeutics with a Neutral rating and $16 price target, telling investors that he finds the company's proprietary TCR Fusion-Construct Tcells, or TRuC-T cells, platform promising, but that its clinical programs are "too early to call."
03/11/19
03/11/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. TCR2 Therapeutics (TCRR) initiated with an Outperform at SVB Leerink, Wedbush, and BMO Capital, while being initiated with a Buy at Jefferies. 2. Barings BDC (BBDC) resumed with an Outperform at Wells Fargo. 3. Avedro (AVDR) initiated with an Overweight at JPMorgan while being initiated with an Outperform at SVB Leerink and Cowen. 4. Anchiano Therapeutics (ANCN) initiated with a Buy at Ladenburg and an Outperform at Oppenheimer. 5. CytomX Therapeutics (CTMX) initiated with an Overweight at Barclays. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
03/11/19
JEFF
03/11/19
INITIATION
Target $31
JEFF
Buy
Jefferies starts TCR2 Therapeutics with Buy rating, $31 price target
Jefferies analyst Biren Amin initiated coverage of TCR2 Therapeutics with a Buy rating and $31 price target. The company is developing a "broad pipeline" centered on its TRuC technology that endows certain advantageous properties to T-cells for targeting solid tumors, where CAR-Ts have not seen much success, Amin tells investors in a research note. While early in development, the analyst believes TCR2 may offer a differentiated approach.
03/11/19
LEER
03/11/19
INITIATION
Target $27
LEER
Outperform
TCR2 Therapeutics initiated with an Outperform at SVB Leerink
SVB Leerink analyst Jonathan Chang initiated TCR2 Therapeutics with an Outperform rating and $27 price target. In a research note to investors, Chang says he has received positive feedback from MEDACorp Key Opinion Leaders on the company's T-Cell Receptor Fusion Construct pipeline based on the preclinical data to date that highlights the potential of TCR2's approach. The analyst maintains a positive long-term view of the stock based on the experienced management team and potentially transformative platform with broad therapeutic applicability.
TCON TRACON Pharmaceuticals
$0.45

0.02 (4.65%)

04/12/19
BTIG
04/12/19
DOWNGRADE
BTIG
Neutral
TRACON Pharmaceuticals downgraded to Neutral from Buy at BTIG
12/26/18
BTIG
12/26/18
NO CHANGE
Target $9
BTIG
Buy
TRACON Pharmaceuticals price target lowered to $9 from $13 at BTIG
BTIG analyst Robert Hazlett lowered his price target on TRACON Pharma to $9 after the company's recent announcement that its Phase 2b TRAXAR trial of TRC105+Intyla in renal cell carcinoma, or RCC, did not meet the primary endpoint of improving progression free survival. The analyst states that the findings have led him to remove the RCC estimates from his model, leading to a lower price target. Hazlett is keeping his Buy rating on Tracon Pharma as he continues to have "material expectations for 105 in angiosarcoma, as well as its opportunities in wet AMD with DE-122 and prostate cancer with TRC253.
ESPR Esperion
$37.70

-1.27 (-3.26%)

05/06/19
BOFA
05/06/19
UPGRADE
BOFA
Neutral
Esperion upgraded to Neutral from Underperform at BofA/Merrill
06/27/19
JMPS
06/27/19
NO CHANGE
Target $153
JMPS
Outperform
Esperion funding deal with Oberland a positive, says JMP Securities
JMP Securities analyst Jason Butler said he views Esperion's funding transaction with Oberland Capital Management as a positive step for the company that provides it with optionality to optimize investment into bempedoic acid's commercial launch. The capped revenue-based funding agreement provides substantial immediate capital and strengthens the company's resources, said Butler, who maintains an Outperform rating and $153 price target on Esperion shares.
06/27/19
JEFF
06/27/19
NO CHANGE
Target $85
JEFF
Buy
Esperion funding agreement brings flexibility into 2020, says Jefferies
Esperion's debt financing brings in an immediate $125M, lifting the company's total pro-forma cash to $355M, and gives it flexibility going into 2020, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the deal as a non-dilutive, "fundamentally good access to cash," that helps shore up Esperion's balance sheet "in case of uncertainty and macro risk in 2020." He keeps a Buy rating on the shares with an $85 price target.
05/29/19
GSCO
05/29/19
DOWNGRADE
Target $50
GSCO
Sell
Esperion downgraded to Sell from Neutral at Goldman Sachs
Goldman Sachs analyst Paul Choi downgraded Esperion Therapeutics to Sell from Neutral with an unchanged price target of $50. With the regulatory path for bempedoic acid "looking clear," the analyst downgrades the shares on valuation following the recent outperformance. He sees the launch in 2020 as the next driver of the stock.
RCUS Arcus Biosciences
$7.30

-0.155 (-2.08%)

06/05/19
SBSH
06/05/19
NO CHANGE
Target $15
SBSH
Buy
Arcus Biosciences price target lowered to $15 from $25 at Citi
Citi analyst Yigal Nochomovitz lowered his price target for Arcus Biosciences to $15 from $25 saying the Phase I data for the company's AB928 and AB122 combo in advanced solid tumors were "somewhat underwhelming." An 11% overall response rate is only in-line with other efforts targeting the adenosine pathway, Nochomovitz tells investors in a research note. He believes the data raise the risk that Arcus will succeed in showing a differentiated profile. Nonetheless, the analyst keeps a Buy rating on the shares.
03/18/19
03/18/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. Western Asset Mortgage (WMC) initiated with a Market Perform at Keefe Bruyette. 2. Cars.com (CARS) initiated with a Neutral at Goldman Sachs. 3. Super League Gaming (SLGG) initiated with an Outperform at Northland. 4. Arcus Biosciences (RCUS) initiated with a Buy at BTIG, while Momenta (MNTA) initiated with a Neutral. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
05/24/19
SBSH
05/24/19
INITIATION
Target $25
SBSH
Buy
Arcus Biosciences assumed with a Buy at Citi
Citi analyst Yigal Nochomovitz assumed coverage of Arcus Biosciences with a Buy rating and $25 price target. The analyst sees an attractive risk/reward profile ahead of clinical data from the company's chemo/PD-1 combo trials in multiple cancers with lead compound AB928 in mid and the second half of 209. He sees potential for 5%-10% upside from each of three key data events expected in 2019.
03/18/19
BTIG
03/18/19
INITIATION
Target $20
BTIG
Buy
Arcus Biosciences initiated with a Buy at BTIG
BTIG analyst Thomas Shrader initiated Arcus Biosciences with a Buy rating and a price target of $20, citing the company's work in chemotherapy and its focus on "driving antitumor immune responses beyond the level achievable by immune checkpoint inhibitors." The analyst sees its data released thus far as "compelling" and notes "several trials" currently enrolling with data expected in mid-2019, with results that could potentially "establish proof of biology and validate patient selection biomarkers." Shrader further notes that Arcus Biosciences' $260M in cash "gives the company runway to optimize its long-term strategy."
SGMO Sangamo
$11.75

-0.22 (-1.84%)

07/08/19
PIPR
07/08/19
NO CHANGE
PIPR
Overweight
BioMarin's Valrox maintains competitive advantage, says Piper Jaffray
After BioMarin (BMRN) announced that the company will submit regulatory filings for Valrox to both the FDA and EMA in Q4, and after the company and competitive partners Sangamo (SGMO) and Pfizer (PFE) both presented updates at this weekend's International Society on Thrombosis and Hemostasis meeting, Piper Jaffray analyst Christopher Raymond said that he still believes the company's roughly 2-year head start puts Valrox at a competitive advantage. Following the confirmation on timing for accelerated filing, Raymond said he would continue to be a buyer of BioMarin shares and he keeps an Overweight rating on the stock.
07/26/19
ADAM
07/26/19
NO CHANGE
Target $37
ADAM
Buy
Homology Medicines selloff yesterday a buying opportunity, says Canaccord
Canaccord Genuity analyst Michelle Gilson attributes the selloff yesterday in shares of Homology Medicines (FIXX) to a pre-printed, and not peer-reviewed, paper that did not support the company's in vitro data around HR-mediated gene editing. The paper's author, who has previously worked with Sangamo Therapeutics (SGMO) on ZFN-mediated editing, was unable to induce homologous recombination without a nuclease, Gilson tells investors in a research note. "It is tough to understand why an author would choose this route of publication for a study of this nature," says the analyst. She sees "several key differences" between the author's and Homology's in vitro experiments. Further, Homology's technology has been externally validated, allowing Novartis (NVS) and other labs to perform their own in-house experiments using Homology plasmids, Gilson contends. She adds that following this validation, Novartis entered into a collaboration specifically revolving around Homology's gene editing technology for ophthalmic targets. The analyst keeps a Buy rating on Homology Medicines with a $37 price target. Gilson views the selloff in the shares as a buying opportunity into the Phase 1/2 pheNIX data by the end of 2019 for HMI-102 gene therapy in phenylketonuria.
07/12/19
JEFF
07/12/19
NO CHANGE
Target $19
JEFF
Buy
Sangamo should be bought at current share levels, says Jefferies
Jefferies analyst Maury Raycroft attributes the recent weakness in shares of Sangamo Therapeutics (SGMO) to negative sentiment related to BioMarin's (BMRN) valrox's durability. The market may be assuming all hemophilia A gene therapies are the same, Raycroft tells investors in a research note. However, he believes Sangamo's SB-525 could be "best-in-class" and keeps a Buy rating on the shares with a $19 price target. The analyst recommends buying the stock at current levels for the company's hemophilia A opportunity and "robust" pipeline.
04/02/19
WELS
04/02/19
NO CHANGE
Target $34
WELS
Outperform
Sangamo price target raised to $34 from $24 at Wells Fargo
Wells Fargo analyst Jim Birchenough raised his price target for Sangamo Therapeutics to $34 from $24 following this morning's clinical update on the company's gene therapy, gene editing and cell therapy pipeline. The stock in morning trading is up 35%, or $3.35, to $12.88. The update was better than expected, particularly for hemophilia gene therapy and beta thalassemia ex vivo gene editing, Birchenough tells investors in a research note. The analyst is "encouraged" by Sangamo's progress against the higher technical hurdle of in vivo genome editing. He believes direct evidence of genome editing, "strong" fetal hemoglobin response and early signs of transfusion independence bode well for ultimate success and should translate into improved likelihood of success in the larger opportunity of sickle cell disease. The analyst reiterates an Outperform rating on Sangamo Therapeutics.
CRSP Crispr Therapeutics
$50.20

1.22 (2.49%)

08/01/19
08/01/19
INITIATION

Fly Intel: Top analyst initiations
Catch up on today's top analyst initiations with this list compiled by The Fly: 1. AMD (AMD) and Maxim Integrated (MXIM) initiated with a Hold at Benchmark. 2. Amag Pharmaceuticals (AMAG) and Cassava Sciences (SAVA) initiated with a Buy at H.C. Wainwright. 3. Crispr Therapeutics (CRSP) initiated with a Buy at Jefferies. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/30/19
ROTH
07/30/19
NO CHANGE
Target $65
ROTH
Buy
Crispr Therapeutics price target raised to $65 from $50 at Roth Capital
Roth Capital analyst Tony Butler raised his price target for Crispr Therapeutics to $65 from $50 after the company reported ending Q2 with $427.9M in cash, which is expected to support operations through 2020, and announced that the first TDT patient treated with CTX001 remains transfusion-independent beyond four months and that the FIH trial of CTX110 in NHL was initiated. The analyst reiterates a Buy rating on the shares based on his continued positive outlook.
07/30/19
PIPR
07/30/19
NO CHANGE
Target $100
PIPR
Overweight
Piper reiterates $100 price target on Crispr Therapeutics post Q2 results
Crispr Therapeutics ended Q2 with cash of $428M, and when including the $175M Vertex upfront and draw-downs, the company could now hold pro forma cash of ~$656M, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. Crispr announced that the first beta thalassemia patient remains transfusion independent for greater than four months since engraftment, representing the first clinical proof of concept for a CRISPR/Cas9 therapy, adds the analyst. Further, he notes that the first sickle cell disease patient was treated with CTX001 in the U.S. Tenthoff reiterates an Overweight rating on Crispr Therapeutics with a $100 price target.
08/01/19
JEFF
08/01/19
INITIATION
Target $64
JEFF
Buy
Crispr Therapeutics initiated with a Buy at Jefferies
Jefferies analyst Maury Raycroft started Crispr Therapeutics with a Buy rating and $64 price target. The company offers the best CRISPR/Cas9 development risk/reward profile, Raycroft tells investors in a research note. He believes that starting with sickle cell disease and beta-thalassemia will "de-risk" its broader pipeline. Crispr Therapeutics has "made strategically sound and differentiated decisions" that should play out in its favor for the longer term, contends the analyst.
FIXX Homology Medicines
$15.79

(0.00%)

07/26/19
HCWC
07/26/19
NO CHANGE
Target $36
HCWC
Buy
Paper on Homology falls short, selloff brings entry point, says H.C. Wainwright
H.C. Wainwright analyst Debjit Chattopadhyay believes the selloff yesterday in shares of Homology Medicines provides a "compelling" entry point. An attempt at a scientific publication questioning the validity of nonnuclease based gene editing, first posted on July 19 in bioRxiv, made rounds on the Street during the afternoon trading session yesterday and knocked about 20% of Homology's market capitalization, Chattopadhyay tells investors in a research note. The crux of the paper revolves around the inability of the authors to replicate the high integration efficiencies achieved by AAVHSCs with replicas of AAVHSC13 and AAVHSC17 derived from a mutated AAV9. "While this is an admirable effort, we think it falls short in several ways," says Chattopadhyay. He keeps a Buy rating on Homology Medicines with a $36 price target.
07/26/19
COWN
07/26/19
NO CHANGE
COWN
Outperform
Homology Medicines weakness overdone after academic paper, says Cowen
Cowen analyst Phil Nadeau noted that Homology Medicines shares have declined 25% since the release of an academic paper questioning the efficiency of homologous recombination-based genome editing by clade F AAVs. Homology's lead program in adult PKU does not use this technology, said Nadeau, who also pointed to "notable shortcomings" in the paper. He keeps an Outperform rating on Homology shares, contending that the weakness in the stock has been overdone.
04/11/19
EVER
04/11/19
INITIATION
Target $29
EVER
Outperform
Homology Medicines initiated with an Outperform at Evercore ISI
Evercore ISI analyst Ravi Mehrotra initiated Homology Medicines with an Outperform rating and a price targets of $29. The analyst says the company is "unique" within his gene therapy universe as it has "both gene therapy and gene editing capabilities using its proprietary AAVHSC vectors." Mehrotra adds that the initial data from Homology Medicines' lead program HMI-102 is expected in the second half of the year and "will help validate the company's vectors."
SNDX Syndax
$9.94

-0.08 (-0.80%)

03/08/19
NOMU
03/08/19
NO CHANGE
Target $16
NOMU
Buy
Syndax price target raised to $16 from $12 at Nomura Instinet
Nomura Instinet analyst Christopher Marai raised his price target for Syndax Pharmaceuticals to $16 following the company's Q4 results and keeps a Buy rating on the shares. The analyst says Syndax is "prioritizing for success" in 2019 and beyond.
05/21/19
SBSH
05/21/19
NO CHANGE
Target $12
SBSH
Buy
Syndax can trade to $23 on positive Phase 3 data, says Citi
Citi analyst Joel Beatty believes shares of Syndax Pharmaceuticals could trade up to $23 if the company's the Phase 3 trial of entinostat in metastatic breast cancer is positive. The analyst, who sees the stock trading down to $2 if the trial fails, assigns a 50% probability of success. He views the data, expected in fall 2019 or spring 2020 as the key catalyst for Syndax. Beatty keeps a Buy rating on the shares.
03/08/19
HCWC
03/08/19
NO CHANGE
Target $16
HCWC
Buy
Syndax price target lowered to $16 from $22 at H.C. Wainwright
H.C. Wainwright analyst Edward White lowered his price target for Syndax Pharmaceuticals to $16 due to removing entinostat in combination with checkpoint inhibitors in non-small cell lung cancer and melanoma from his valuation. The analyst keeps a Buy rating on the shares.
03/08/19
BTIG
03/08/19
NO CHANGE
Target $19
BTIG
Buy
Syndax price target lowered to $19 from $29 at BTIG
BTIG analyst Robert Hazlett lowered his price target on Syndax to $19 after its announced miss in the primary Progression-free survival Phase 2 study for Entinostat immuno-oncology combinations in Triple-negative breast cancer and ovarian cancer. The analyst says the company is now prioritizing its pipeline to focus on Entinostat in breast cancer with upcoming readouts expected in Q2. Hazlett is keeping his Buy rating on Syndax.

TODAY'S FREE FLY STORIES

ALSN

Allison Transmission

$43.06

-0.96 (-2.18%)

15:30
08/23/19
08/23
15:30
08/23/19
15:30
Conference/Events
Allison Transmission management to meet with RBC Capital »

Meeting to be held In…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

15:30
08/23/19
08/23
15:30
08/23/19
15:30
General news
Treasury Action: bond yields have inched up from intraday lows »

Treasury Action: bond…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

, RUT

Russell 2000 Index

$0.00

(0.00%)

15:22
08/23/19
08/23
15:22
08/23/19
15:22
Technical Analysis
On The Fly: Weekly technical notes for Russell 2000 »

The Russell 2000 (RUT) at…

IWM

iShares Trust Russell 2000 Index Fund

$146.13

-3.92 (-2.61%)

RUT

Russell 2000 Index

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
08/23/19
08/23
15:17
08/23/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

$0.00

(0.00%)

15:16
08/23/19
08/23
15:16
08/23/19
15:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FCAU

Fiat Chrysler

$12.53

-0.24 (-1.88%)

15:15
08/23/19
08/23
15:15
08/23/19
15:15
Options
Fiat Chrysler put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SPX

S&P 500

$0.00

(0.00%)

, SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

15:12
08/23/19
08/23
15:12
08/23/19
15:12
Technical Analysis
On The Fly: Weekly technical notes for S&P 500 »

At time of writing the…

SPX

S&P 500

$0.00

(0.00%)

SPY

SPDR S&P 500 ETF Trust

$285.78

-6.58 (-2.25%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DDOG

Datadog

$0.00

(0.00%)

15:11
08/23/19
08/23
15:11
08/23/19
15:11
Syndicate
Datadog files S-1 for IPO, seeks to list on Nasdaq with symbol 'DDOG' »

Datadog filed an S-1 with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HIIQ

Health Insurance Innovations

$18.17

-0.87 (-4.57%)

15:05
08/23/19
08/23
15:05
08/23/19
15:05
Options
Health Insurance Innovations call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Sep

  • 20

    Sep

INCY

Incyte

$82.37

-3.2 (-3.74%)

, LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

14:58
08/23/19
08/23
14:58
08/23/19
14:58
Hot Stocks
Eli Lilly, Incyte announce baricitinib meets primary endpoint in Phase 3 trial »

Eli Lilly (LLY) and…

INCY

Incyte

$82.37

-3.2 (-3.74%)

LLY

Eli Lilly

$110.50

-1.13 (-1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Sep

  • 09

    Sep

  • 16

    Sep

  • 02

    Oct

  • 23

    Oct

EPD

Enterprise Products

$28.35

-0.605 (-2.09%)

14:55
08/23/19
08/23
14:55
08/23/19
14:55
Options
Enterprise Products put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

, LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

14:54
08/23/19
08/23
14:54
08/23/19
14:54
On The Fly
Box Office Battle: 'Angel has Fallen' looking to swoop into top spot »

Welcome to "Box Office…

LGF.A

Lionsgate

$10.52

-0.28 (-2.59%)

LGF.B

Lionsgate

$10.01

-0.205 (-2.01%)

SNE

Sony

$53.87

-0.91 (-1.66%)

CMCSA

Comcast

$42.75

-1.01 (-2.31%)

CMCSK

Comcast

$0.00

(0.00%)

T

AT&T

$34.95

-0.44 (-1.24%)

CBS

CBS

$42.02

-1.43 (-3.29%)

DIS

Disney

$133.09

-2.98 (-2.19%)

VIA

Viacom

$27.31

-0.28 (-1.01%)

VIAB

Viacom

$25.01

-0.85 (-3.29%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 05

    Sep

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Oct

  • 27

    Oct

QSR

Restaurant Brands

$76.37

0.94 (1.25%)

14:45
08/23/19
08/23
14:45
08/23/19
14:45
Options
Restaurant Brands call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

14:45
08/23/19
08/23
14:45
08/23/19
14:45
General news
Fed funds futures surge on the downdraft in stocks »

Fed funds futures surge…

OSW

OneSpaWorld

$15.84

-0.22 (-1.37%)

14:41
08/23/19
08/23
14:41
08/23/19
14:41
Conference/Events
OneSpaWorld management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 28

    Aug

OPRX

OptimizeRx

$15.16

-0.39 (-2.51%)

14:38
08/23/19
08/23
14:38
08/23/19
14:38
Conference/Events
OptimizeRx management to meet with William Blair »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 12

    Sep

APPN

Appian

$60.63

0.29 (0.48%)

14:37
08/23/19
08/23
14:37
08/23/19
14:37
Conference/Events
Appian management to meet with William Blair »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Aug

  • 27

    Aug

ET

Energy Transfer LP

$13.35

-0.31 (-2.27%)

14:35
08/23/19
08/23
14:35
08/23/19
14:35
Options
Energy Transfer put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NKTR

Nektar

$17.04

0.05 (0.29%)

14:25
08/23/19
08/23
14:25
08/23/19
14:25
Options
Nektar call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Aug

14:20
08/23/19
08/23
14:20
08/23/19
14:20
General news
Treasury Action: yields remain sharply lower on a flight to safety »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

14:17
08/23/19
08/23
14:17
08/23/19
14:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

, DIS

Disney

$133.27

-2.8 (-2.06%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Periodicals
Sinclair CEO eyes more regional sports network acquisitions, WSJ reports »

Sinclair Broadcast (SBGI)…

SBGI

Sinclair Broadcast

$43.19

-1.24 (-2.79%)

DIS

Disney

$133.27

-2.8 (-2.06%)

T

AT&T

$34.97

-0.425 (-1.20%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Sep

  • 10

    Sep

  • 11

    Sep

  • 23

    Sep

  • 23

    Oct

$NYE

NYSE Market Internals

$0.00

(0.00%)

14:16
08/23/19
08/23
14:16
08/23/19
14:16
Technical Analysis
NYSE market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FANG

Diamondback Energy

$95.83

-3.315 (-3.34%)

14:15
08/23/19
08/23
14:15
08/23/19
14:15
Options
Diamondback Energy put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 27

    Aug

  • 11

    Sep

14:10
08/23/19
08/23
14:10
08/23/19
14:10
General news
Action Economics Survey results: »

Action Economics Survey…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.